3 SEHK Dividend Stocks Yielding Up To 5.5%

In This Article:

The Hong Kong market has seen a significant boost recently, driven by China's robust stimulus measures aimed at revitalizing its economy. This positive sentiment has also lifted the Hang Seng Index, which gained 13% in response to these developments. In this favorable economic climate, dividend stocks can offer a stable income stream and potential for capital appreciation. Here are three SEHK dividend stocks yielding up to 5.5% that might be worth considering for their steady returns and resilience amid current market conditions.

Top 10 Dividend Stocks In Hong Kong

Name

Dividend Yield

Dividend Rating

Chongqing Rural Commercial Bank (SEHK:3618)

7.93%

★★★★★★

Consun Pharmaceutical Group (SEHK:1681)

8.42%

★★★★★☆

China Hongqiao Group (SEHK:1378)

9.09%

★★★★★☆

Bank of China (SEHK:3988)

7.29%

★★★★★☆

Lion Rock Group (SEHK:1127)

8.09%

★★★★★☆

China Construction Bank (SEHK:939)

7.42%

★★★★★☆

PC Partner Group (SEHK:1263)

9.46%

★★★★★☆

Tianjin Development Holdings (SEHK:882)

7.28%

★★★★★☆

Sinopharm Group (SEHK:1099)

4.59%

★★★★★☆

China Electronics Huada Technology (SEHK:85)

8.47%

★★★★★☆

Click here to see the full list of 87 stocks from our Top SEHK Dividend Stocks screener.

Let's uncover some gems from our specialized screener.

Essex Bio-Technology

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Essex Bio-Technology Limited is an investment holding company that develops, manufactures, distributes, and sells bio-pharmaceutical products in the People’s Republic of China, Hong Kong, and internationally with a market cap of HK$1.53 billion.

Operations: Essex Bio-Technology Limited generates revenue primarily from its surgical segment (HK$871.44 million) and ophthalmology segment (HK$747.39 million).

Dividend Yield: 4.4%

Essex Bio-Technology's recent share repurchase program, authorized to buy back up to 56.75 million shares, is expected to enhance net asset value and earnings per share. The company declared an interim dividend of HK$0.06 per share for the first half of 2024 despite a slight decline in sales and net income compared to last year. With a payout ratio of 22.7% and cash payout ratio of 32.3%, dividends are well-covered by earnings and cash flows, though historical dividend payments have been volatile and lower than top-tier payers in Hong Kong.

SEHK:1061 Dividend History as at Oct 2024
SEHK:1061 Dividend History as at Oct 2024

Shandong Weigao Group Medical Polymer

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Shandong Weigao Group Medical Polymer Company Limited focuses on the research, development, production, wholesale, and sale of medical devices in China and has a market cap of HK$25.69 billion.